The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II, multicenter trial of nivolumab (Nivo) and brentuximab vedotin (BV) in patients (Pts) with untreated Hodgkin lymphoma (HL) over the age of 60 years or unable to receive standard ABVD chemotherapy: Results of a study of Academic and Community Cancer Research United (ACCRU) RU051505I.
 
Bruce D. Cheson
Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca; Bayer; Celgene; Epizyme; Gilead Sciences; Karyopharm Therapeutics; Morphosys; Parexel; Pharmacyclics/Janssen; Roche/Genentech; SymBio Pharmaceuticals; TG Therapeutics
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Roche/Genentech (Inst); Seagen (Inst); TG Therapeutics (Inst); Trillium Therapeutics (Inst)
Travel, Accommodations, Expenses - SymBio Pharmaceuticals
 
Nancy L. Bartlett
Consulting or Advisory Role - Seagen
Research Funding - ADC Therapeutics (Inst); Autolus (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Forty Seven (Inst); Genentech (Inst); Immune Design (Inst); Janssen (Inst); Kite, a Gilead company (Inst); Merck (Inst); Millennium (Inst); Pharmacyclics (Inst); Seagen (Inst)
 
Betsy LaPlant
No Relationships to Disclose
 
Hun Ju Lee
Consulting or Advisory Role - Bristol-Myers Squibb; Guidepoint Global
Research Funding - Bristol-Myers Squibb; Celgene; Celgene; Oncternal Therapeutics; Seagen; Takeda
 
Ranjana H. Advani
Honoraria - Takeda
Consulting or Advisory Role - AstraZeneca; Bayer; Celgene; Cell Medica; Genentech/Roche; Gilead Sciences; Kite, a Gilead company; Kyowa Hakko Kirin; Portola Pharmaceuticals; Sanofi; Seagen; Takeda
Research Funding - Agensys (Inst); Celgene (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Infinity Pharmaceuticals (Inst); Janssen (Inst); Kura Oncology (Inst); Merck (Inst); Millennium (Inst); Pharmacyclics (Inst); Regeneron (Inst); Seagen (Inst)
 
Beth Christian
Consulting or Advisory Role - Genentech; Seagen
Research Funding - Acerta Pharma; Celgene; Cephalon; Genentech/Roche; Immunomedics; Janssen; Merck; Millenium Pharamceuticals; Seagen; Triphase
 
Catherine S. Magid Diefenbach
Stock and Other Ownership Interests - Gilead Sciences
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Celgene; Genentech/Roche; Janssen; Merck; MorphoSys; Seagen
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); Incyte (Inst); Janssen (Inst); LAM Therapeutics (Inst); MEI Pharma (Inst); Merck (Inst); Millennium (Inst); Roche/Genentech (Inst); Seagen (Inst); Trillium Therapeutics (Inst)
 
Tatyana Feldman
Honoraria - Abbvie; Bayer; Bristol-Myers Squibb; Kite, a Gilead company; Pharmacyclics/Janssen; Seagen; Takeda
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Seagen
Speakers' Bureau - Abbvie; Celgene; Janssen; Kite, a Gilead company; Pharmacyclics; Seagen
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Cell Medica (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Kyowa Hakko Kirin (Inst); Pfizer (Inst); Portola Pharmaceuticals (Inst); Roche (Inst); Seagen (Inst); Trillium Therapeutics (Inst); Viracta Therapeutics (Inst); Viracta Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; Kite, a Gilead company; Pharmacyclics; Seagen; Takeda
 
Stephen M. Ansell
Honoraria - Research to Practice; WebMD
Research Funding - Affimed Therapeutics (Inst); AI Therapeutics (Inst); Bristol-Myers Squibb (Inst); Pfizer (Inst); Regeneron (Inst); Seagen (Inst); Trillium Therapeutics (Inst)